T
Thomas A Rasmussen
Researcher at University of Melbourne
Publications - 73
Citations - 3085
Thomas A Rasmussen is an academic researcher from University of Melbourne. The author has contributed to research in topics: Immune system & Viral load. The author has an hindex of 24, co-authored 64 publications receiving 2571 citations. Previous affiliations of Thomas A Rasmussen include Aarhus University & Peter MacCallum Cancer Centre.
Papers
More filters
Journal ArticleDOI
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A Rasmussen,Martin Tolstrup,Christel R. Brinkmann,Rikke Olesen,Christian Erikstrup,Ajantha Solomon,Anni Winckelmann,Sarah Palmer,Charles A. Dinarello,Maria J. Buzon,Maria J. Buzon,Mathias Lichterfeld,Mathias Lichterfeld,Sharon R Lewin,Sharon R Lewin,Lars Østergaard,Ole S. Søgaard +16 more
TL;DR: Panobinostat effectively disrupts HIV latency in vivo and is a promising candidate for future combination clinical trials aimed at HIV eradication, however, panobinostats did not reduce the number of latently infected cells and this approach may need to be combined with others to significantly affect the latent HIV reservoir.
Journal ArticleDOI
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
Ole S. Søgaard,Mette E. Graversen,Steffen Leth,Rikke Olesen,Christel R. Brinkmann,Sara K. Nissen,Anne Sofie Høgh Kølbæk Kjær,Mariane H. Schleimann,Paul W. Denton,William J. Hey-Cunningham,Kersten K. Koelsch,Giuseppe Pantaleo,Kim Krogsgaard,Maja A. Sommerfelt,Rémi Fromentin,Nicolas Chomont,Thomas A Rasmussen,Lars Østergaard,Martin Tolstrup +18 more
TL;DR: A proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous 5 mg/m2 romidepsin (Celgene) once weekly for 3 weeks while maintaining ART demonstrates that significant reversal of HIV- 1 latency in vivo is possible without blunting T cell-mediated immune responses.
Journal ArticleDOI
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.
Thomas A Rasmussen,Ole S. Søgaard,Christel R. Brinkmann,Fiona Wightman,Sharon R Lewin,Jesper Melchjorsen,Charles A. Dinarello,Lars Østergaard,Martin Tolstrup +8 more
TL;DR: Panobinostat was significantly more potent than all other HDAC inhibitors and induced virus production even in the very low concentration range 8–31 nM and is now being advanced into clinical testing against latent HIV infection.
Journal ArticleDOI
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
Steffen Leth,Steffen Leth,Mariane H. Schleimann,Mariane H. Schleimann,Sara K. Nissen,Sara K. Nissen,Jesper F Højen,Jesper F Højen,Rikke Olesen,Mette E. Graversen,Mette E. Graversen,Sofie E. Jørgensen,Sofie E. Jørgensen,Anne Sofie Høgh Kølbæk Kjær,Anne Sofie Høgh Kølbæk Kjær,Paul W. Denton,Paul W. Denton,Alejandra Mørk,Maja A. Sommerfelt,Kim Krogsgaard,Lars Østergaard,Lars Østergaard,Thomas A Rasmussen,Martin Tolstrup,Martin Tolstrup,Ole Schmeltz Søgaard,Ole Schmeltz Søgaard +26 more
TL;DR: This in-vivo combinatorial approach provides the first evidence for the feasibility of a combined shock and kill strategy, but also emphasises that further optimisation of this strategy is needed to achieve a sizeable effect on the latent reservoir that will translate into clinically measurable benefits for people living with HIV-1.
Journal ArticleDOI
Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
TL;DR: An overview of the initial experiences with the use of latency-reversing agents (LRAs) in clinical trials in HIV is provided to discuss and contrast results arising from these studies.